TNXP stock forecast, quote, news & analysis
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases... Show more
Why Tonix Pharmaceuticals (TNXP) Stock Is Down -40% in the Last 30 Days
Key Takeaways
- Tonix Pharmaceuticals (TNXP) shares have fallen roughly 40% over the trailing 30 days, sliding from about $6.64 to near $4.00.
- The move extends a broader multi-month decline, with the stock down more than 70% from levels near $14 in early September.
- Third-quarter 2026 results showed Tonmya net sales rising 37% quarter-over-quarter to about $15 million, but a wider-than-expected net loss weighed on sentiment.
- Dr. Reddy's Laboratories filed a Paragraph IV ANDA patent certification against Tonmya on October 1, 2026, adding a generic-competition overhang.
- Elevated cash burn and a cash runway projected into early third-quarter 2027 have kept financing and potential dilution concerns in focus.
- For additional detail, explore Tonix's Price Targets, Earnings, and Forecast pages.
- Investors seeking systematic trading insights can also review Trending AI Robots.
Tonix Pharmaceuticals (TNXP) Company Overview and Market Position
Tonix Pharmaceuticals Holding Corp. is a commercial-stage biopharmaceutical company focused on central nervous system (CNS) disorders and, more recently, immunology and infectious disease. Its lead commercial product is Tonmya (cyclobenzaprine HCl sublingual tablets), the first new FDA-approved medicine for fibromyalgia in more than 15 years. Tonmya received U.S. approval in August 2025 and was commercially launched in November 2025. The company also markets two migraine products, Zembrace SymTouch and Tosymra.
Tonix's clinical pipeline includes TNX-102 SL in development for major depressive disorder, the anti-OspA monoclonal antibody TNX-4800 for Lyme disease prevention, and TNX-1500 (mosdaprubart) for the prevention of kidney transplant rejection. Investors follow the stock closely for the trajectory of the Tonmya launch, payer coverage expansion, pipeline milestones, and the company's cash position.
Tonix Pharmaceuticals (TNXP) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, TNXP shares declined roughly 40%, falling from a closing price of approximately $6.64 to about $4.00 at the latest available reading. The selloff was broad-based and persistent rather than the result of a single session, with lower highs and lower lows across the period.
The quarterly picture is even steeper. Entering September, the stock traded near $14 before beginning a sustained descent that has since erased more than 70% of its value. The decline reflects a combination of ongoing operating losses, rising expenses tied to the Tonmya commercial launch and clinical programs, a generic patent challenge, and financing overhang that has pressured a small-cap biotechnology name already exposed to risk-off sentiment.
What Drove TNXP Stock Price in the Last 30 Days
The most significant near-term catalyst was the company's third-quarter 2026 earnings report released on November 9. Tonix reported net product revenue of approximately $17.2 million, including about $15 million in Tonmya net sales (up 37% quarter-over-quarter), which modestly exceeded consensus. However, the company posted a net loss of $53.3 million, or $2.89 per share, wider than analyst estimates, as research and development expenses surged to roughly $25.8 million and selling, general, and administrative expenses rose to about $45.6 million.
Compounding the pressure, on October 1, 2026, Tonix disclosed that Dr. Reddy's Laboratories had filed an abbreviated new drug application with a Paragraph IV patent certification challenging Tonmya. While the company said it intends to vigorously defend its intellectual property, the announcement introduced generic-competition uncertainty. Separately, Raymond James lowered its price target on the stock to $14 from $26 while maintaining a Strong Buy rating, and the company's cash position of roughly $163 million, with a runway into early third-quarter 2027, kept dilution concerns front of mind.
What Drove TNXP Stock Performance Over the Last Quarter
Over the last quarter, TNXP's decline has been driven less by any single event and more by a sustained repricing of execution and balance-sheet risk. Although Tonmya's launch metrics improved — with prescriptions up 28% quarter-over-quarter to 16,375, an expanded 150-representative sales force effective September 1, and payer coverage reaching about 53% of U.S. covered lives — these gains have been offset by escalating launch and pipeline costs and a shrinking cash balance.
The broader environment has also weighed on the shares. Small- and micro-cap biotech names with heavy cash burn and near-term financing needs have faced particular pressure, and the generic patent challenge further clouded the long-term revenue durability of Tonix. The result has been a multi-month downtrend that has persisted despite improving underlying commercial fundamentals.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of the platform's top-performing automated trading systems. While Tickeron offers hundreds of AI-driven trading bots covering thousands of tickers, only the most relevant and best-performing bots appear in this featured section. These bots differ widely in trading strategy, holding timeframe, and performance metrics, giving traders the ability to compare approaches side by side. For investors following volatile names like TNXP, the page provides a data-driven way to observe how systematic strategies are navigating shifting market conditions. Exploring the section can help traders identify bots whose methodologies align with their own objectives.
TNXP Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, investors will likely focus on the pace of Tonmya prescription growth and the continued expansion of payer coverage and gross-to-net dynamics, which will shape revenue trajectory in coming quarters. The progress of the Paragraph IV litigation with Dr. Reddy's Laboratories and the company's ability to defend its Tonmya intellectual property will be closely watched, as will the start of the Phase 2 TNX-4800 Lyme disease study and the TNX-1500 kidney transplant program expected in early 2027.
Balance-sheet management remains a key variable. With cash runway projected into early third-quarter 2027, any financing or partnership decisions could influence the share count and investor sentiment. Broader macroeconomic conditions, sector rotation within healthcare, and analyst expectations will also continue to play a role. These are factors to monitor rather than signals of any particular outcome, and no forward-looking statements here constitute investment advice.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
TNXP in -13.81% downward trend, falling for three consecutive days on November 11, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where TNXP declined for three days, in 356 of 377 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Aroon Indicator for TNXP entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for TNXP just turned positive on October 27, 2026. Looking at past instances where TNXP's MACD turned positive, the stock continued to rise in 21 of 31 cases over the following month. The odds of a continued upward trend are 68%.
Following a +1.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where TNXP advanced for three days, in 180 of 222 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
TNXP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.366) is normal, around the industry mean (3.498). P/E Ratio (-0.362) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (5.176) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. TNXP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TNXP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in developing and manufacturing pharmaceuticals
Industry Biotechnology